Zargari Omid, Kimyai-Asadi Arash, Jafroodi Maryam
Department of Dermatology, Guilan University of Medical Sciences, Rasht, Iran.
Pediatr Dermatol. 2004 Nov-Dec;21(6):633-5. doi: 10.1111/j.0736-8046.2004.21603.x.
Although the cutaneous effects of hydroxyurea have been described for patients with sickle cell anemia, myeloproliferative disorders, and psoriasis, there are no reports of cutaneous adverse effects from hydroxyurea when used for patients with intermediate thalassemia. Therefore 43 patients with intermediate thalassemia treated with hydroxyurea were examined by a dermatologist, and pertinent cutaneous findings were recorded. These patients had received hydroxyurea for a mean of 15.5 months. Nineteen had cutaneous hyperpigmentation, eight had xerosis, and three were found to have one cafe au lait macule each. Eleven patients had nail abnormalities, including nail ridging, partial leukonychia, and longitudinal melanonychia. There were no cases of leg ulceration. It was concluded that the risk of developing leg ulcers and pigmentary disorders appears to be related to the underlying disease being treated, as well as to a patient's age, gender, and pigmentation.
尽管已描述了羟基脲对镰状细胞贫血、骨髓增殖性疾病和银屑病患者的皮肤影响，但对于中间型地中海贫血患者使用羟基脲时，尚无皮肤不良反应的报告。因此，一名皮肤科医生对43例接受羟基脲治疗的中间型地中海贫血患者进行了检查，并记录了相关的皮肤表现。这些患者接受羟基脲治疗的平均时间为15.5个月。19例有皮肤色素沉着，8例有皮肤干燥，3例各有1处咖啡牛奶斑。11例患者有指甲异常，包括甲嵴、部分白甲和纵向黑甲。无腿部溃疡病例。得出的结论是，发生腿部溃疡和色素沉着紊乱的风险似乎与所治疗的基础疾病有关，也与患者的年龄、性别和色素沉着有关。
